Evotec SE (EVO) Other Operating Expenses (2009 - 2025)
Evotec SE (EVO) reported Other Operating Expenses of -$248.6 million for Q4 2025, down 246.79% on a YoY basis from $169.4 million in Q4 2024, and down 246.79% sequentially from -$71.7 million in Q4 2024.
Evotec SE (EVO) Other Operating Expenses (2009 - 2025) Analysis & Trends
Evotec SE (EVO) has 8 years of Other Operating Expenses data on file, last reported at -$248.6 million in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses fell 246.79% year-over-year to -$248.6 million; the trailing twelve-month figure through Mar 2026 stood at -$248.6 million (down 246.79% YoY), and the FY2025 full-year result was -$248.7 million, down 246.82% from the prior year.
- Other Operating Expenses eased to -$248.6 million in Q4 2025, from -$71.7 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $77539.5 in Q4 2021 to a low of -$256.5 million in Q4 2023.
- A 5-year average of -$57.7 million and a median of -$3847.9 in 2021 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses sank 443169.24% in 2023 and jumped 72.05% in 2024, its largest moves.
- Tracing EVO's Other Operating Expenses over 5 years: stood at $77539.5 in 2021, then fell by 25.35% to $57882.7 in 2022, then slumped by 443169.24% to -$256.5 million in 2023, then jumped by 72.05% to -$71.7 million in 2024, then sank by 246.79% to -$248.6 million in 2025.
- Business Quant data shows EVO's Other Operating Expenses at -$248.6 million in Q4 2025, -$71.7 million in Q4 2024, and -$256.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -248.59 Mn |
| Dec 31, 2024 | -71.68 Mn |
| Dec 31, 2023 | -256.46 Mn |
| Sep 30, 2023 | -26,697.68 |
| Jun 30, 2023 | -26,815.85 |
| Dec 31, 2022 | 57,882.71 |
| Jun 30, 2022 | 21,223.76 |
| Mar 31, 2022 | 20,031.48 |
| Dec 31, 2021 | 77,539.50 |
| Mar 31, 2021 | 19,001.84 |
| Dec 31, 2020 | 80,130.22 |
| Sep 30, 2010 | 3,250.13 |
| Jun 30, 2010 | 4,510.38 |
| Mar 31, 2010 | -1,241.44 |
| Dec 31, 2009 | 76.12 Mn |
| Jun 30, 2009 | 5,194.69 |
| Mar 31, 2009 | -225.63 |